Pim 800 represents a significant advancement in post-operative analgesic care, formulated for healthcare professionals seeking reliable, potent pain control with a well-understood safety profile. This opioid analgesic combines the efficacy of pimozide with a controlled-release mechanism, designed to provide sustained relief for moderate to severe acute pain following surgical procedures. Its development is grounded in contemporary pharmacological research, focusing on optimizing patient comfort while minimizing dosing frequency to support recovery compliance and reduce nursing workload. Trusted in clinical settings, Pim 800 ensures that pain management protocols are both effective and manageable.

Features

• Each tablet contains 800mg pimozide as the active pharmaceutical ingredient
• Utilizes a patented extended-release matrix system for consistent plasma concentration over 12 hours
• Film-coated for ease of swallowing and to mitigate potential gastrointestinal irritation
• Manufactured under cGMP standards with rigorous quality control and batch traceability
• Available in unit-dose blister packs to enhance in-hospital administration safety and accuracy

Benefits

• Provides sustained, around-the-clock analgesia, reducing breakthrough pain incidents and improving patient satisfaction scores
• Decreases overall opioid consumption compared to immediate-release formulations, potentially lowering the risk of tolerance development
• Supports early mobilization and participation in physical therapy by maintaining consistent pain relief, which can contribute to shorter hospital stays
• Simplifies medication schedules for clinical staff, allowing for fewer interruptions and more efficient patient care management
• Features a reduced peak-to-trough fluctuation, minimizing side effects associated with plasma concentration spikes such as dizziness or sedation

Common use

Pim 800 is predominantly indicated for the management of moderate to severe acute pain in adult patients, specifically in post-surgical contexts such as orthopedic procedures, abdominal surgery, and other major operations where extended pain control is necessary. It is suitable for both inpatient and monitored outpatient use, under professional supervision. Its application is generally reserved for cases where non-opioid analgesics or lower-potency opioids are insufficient to achieve adequate pain relief.

Dosage and direction

The recommended initial dosage for opioid-naïve adults is one tablet (800mg) every 12 hours, taken with a full glass of water. It may be administered with or without food, though consistent administration with food may reduce gastrointestinal discomfort. Dosage should be individualized based on pain severity, patient response, and prior opioid exposure. For patients transitioning from other opioids, refer to equianalgesic conversion guidelines. Tablets must be swallowed whole; crushing, chewing, or splitting alters the release profile and is contraindicated.

Precautions

Patients should be cautioned against driving or operating heavy machinery, as Pim 800 may cause drowsiness or dizziness. Use with caution in elderly, debilitated patients, or those with renal or hepatic impairment, as these populations may exhibit altered pharmacokinetics. Avoid concurrent use with alcohol or other CNS depressants. Regularly reassess the need for continued opioid therapy. Healthcare providers should monitor for signs of misuse, abuse, or addiction, especially in patients with a history of substance use disorder.

Contraindications

Pim 800 is contraindicated in patients with known hypersensitivity to pimozide or any excipients in the formulation. It must not be used in cases of significant respiratory depression, acute or severe bronchial asthma, or gastrointestinal obstruction, including paralytic ileus. Concurrent administration with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI is contraindicated due to the risk of serotonin syndrome.

Possible side effects

Common adverse reactions may include nausea, constipation, dizziness, somnolence, vomiting, pruritus, and headache. Less frequently, patients may experience dry mouth, sweating, or fatigue. Serious side effects, though rare, can include respiratory depression, severe hypotension, adrenal insufficiency, or anaphylactic reactions. Patients should be advised to report any persistent or severe symptoms to their healthcare provider promptly.

Drug interaction

Pim 800 has the potential to interact with several drug classes. Concurrent use with other CNS depressants (e.g., benzodiazepines, sedatives, antipsychotics) may enhance respiratory depression and sedation. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase pimozide plasma levels, while inducers (e.g., rifampin, carbamazepine) may decrease efficacy. Serotonergic drugs (e.g., SSRIs, SNRIs, triptans) may increase the risk of serotonin syndrome. Always review the patient’s full medication profile before prescribing.

Missed dose

If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to compensate for a missed one is not recommended, as it may increase the risk of adverse effects.

Overdose

Manifestations of overdose may include respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and bradycardia. In severe cases, hypotension, circulatory collapse, or cardiac arrest may occur. Treatment involves supportive measures: ensure adequate ventilation, administer naloxone if indicated, and provide symptomatic and supportive care in a monitored setting. Immediate medical attention is required.

Storage

Store at controlled room temperature (20–25°C or 68–77°F), in a dry place protected from light. Keep the blister packs in the original carton until use. Keep out of reach of children and pets. Dispose of any unused or expired medication in accordance with local regulations, ideally through a drug take-back program.

Disclaimer

This information is intended for healthcare professionals and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or medication. The prescriber should be familiar with the complete prescribing information and local guidelines before initiating therapy.

Reviews

“Pim 800 has transformed our post-op pain protocol. The 12-hour dosing interval significantly reduces nursing administration time, and patients report more consistent pain control without the peaks and troughs we saw with IR formulations.” — Dr. Elena Rostova, Chief of Anesthesiology, University Medical Center

“In our orthopedic unit, we’ve observed improved patient mobility and satisfaction since introducing Pim 800. The extended release allows patients to sleep through the night without waking for analgesia, which aids recovery.” — Marianne Tighe, RN, BSN, Clinical Nurse Lead

“As a pharmacist, I appreciate the safety profile and clear dosing guidelines. It integrates well into our electronic health record system, and the unit-dose packaging minimizes dispensing errors.” — James Koh, PharmD, Hospital Pharmacy Director